As a continuation of our interest in the anti-inflammatory activities of Vietnamese plants, we searched for novel anti-inflammatory agents in Eleutherine bulbosa and evaluated the anti-inflammatory effects of an ethanol extract of the rhizome of E. bulbosa (EBE) on lipopolysaccharide-stimulated RAW 264.7 macrophages in vitro and in a collagen antibody-induced arthritic (CAIA) mouse model in vivo. Treatment of the CAIA mice with EBE decreased the incidence of arthritis, especially at a dose of 1000 mg/kg body weight. A significant (P<0.05) decrease in the arthritis score was seen after high-dose EBE treatment between days 10 and 14 in comparison with the negative control. The serum levels of the inflammatory cytokines tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, and IL-10 in the mice were measured using commercial ELISA kits. The results suggest that an ethanol extract of the E. bulbosa rhizome has beneficial effects on inflammatory cytokine regulation in an experimental CAIA model.
LoiD.T. (2001) Glossary of Vietnamese Medicinal Plants and Drugs.Hanoi Publishing House for Science and Technics, 145.
2.
BichD.H., ChungD.Q., ChuongB.X., DongN.T., DamD.T., HienP.V., LoV.N., MaiP.D., ManP.K., NhuD.T., TapN., ToanT. (2004) Medicinal Animals and Plants in Vietnam.Hanoi Science and Technology Publishing House, Hanoi, 1, 698.
3.
AlvesT.M.A., KloosH., ZaniA.L. (2003) Eleutherinone, a novel fungitoxic naphthoquinone from Eleutherine bulbosa (Iridaceae). Memórias do Instituto Oswaldo Cruz, 98, 709–712.
4.
LeM.H., DoT.T.H., PhanV.K., ChauV.M., NguyenT.H.V., NguyenX.N., BuiH.T., PhamQ.L., BuiK.A., KimS.H., HongH.J., KimS., KohY.S., KimY.H. (2013) Chemical constituents of the rhizome of Eleutherine bulbosa and their inhibitory effect on the pro-inflammatory cytokines production in lipopolysaccharide -stimulated bone marrow-derived dendritic cells. Bulletin of the Korean Chemical Society, 34, 633–636.
5.
KimK.N., KoY.J., KangM.C., YangH.M., RohS.W., OdaT., JeonY.J., JungW.K., HeoS.J., YoonW.J., KimD. (2013) Anti-inflammatory effects of trans- 1, 3-diphenyl-2, 3-epoxypropane-1-one mediated by suppression of inflammatory mediators in LPS-stimulated RAW 264.7 macrophages. Food and Chemical Toxicology, 53, 371–375.
6.
KhallafH.A., NosairN.A., AlashkarD.S., AbdellaD.H. (2016) Assessment of serum nitrite level in patients with rheumatoid arthritis, Tanta Medical Journal, 44, 12–15.
7.
AliA.M., HabeebR.A., El-AziziN.O., KhattabD.A., Abo-ShadyR.A., ElkabarityR.H. (2014) Higher nitric oxide levels are associated with disease activity in Egyptian rheumatoid arthritis patients. Revista Brasileira de Reumatologia, 54, 446–451.
8.
NagyG., KonczA., TelaricoT., FernandezD., ErsekB., BuzásE., PerlA. (2010) Central role of nitric oxide in the pathogenesis of rheumatoid arthritis and sysemic lupus erythematosus. Arthritis Research & Therapy, 12, 210–216.
9.
CuzzocreaS. (2006) Role of nitric oxide and reactive oxygen species in arthritis. Current Pharmaceutical Design, 12, 3551–3570.
10.
OECD (Organization for Economic Cooperation and Development). (1996) Guideline for Testing of Chemicals, No 423: Acute Oral Toxicity-Acute Toxic Class Method. Paris: Organisation for Economic Co-operation and Development.
11.
ChernajovskyY., FeldmannM., MainiR.N. (1995) Gene therapy of rheumatoid arthritis via cytokine regulation: future perspectives. British Medical Bulletin, 51, 503–516.
12.
BrennanF.M., McInnesI.B. (2008) Evidence that cytokines play a role in rheumatoid arthritis. The Journal of Clinical Investigation, 118, 3537–3545.
13.
SriranganS., ChoyE.H. (2010) The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2, 247–256.
14.
De BenedettiF., RucciN., Del FattoreA., PeruzziB., ParoR., LongoM., VivarelliM., MuratoriF., BerniS., BallantiP., FerrariS. (2006) Impaired skeletal development in interleukin - 6 - transgenic mice: A model for the impact of chronic inflammation on the growing skeletal system. Arthritis & Rheumatology, 54, 3551–3563.
15.
MatsunoH., YudohK., KatayamaR., NakazawaF., UzukiM., SawaiT., YonezawaT., SaekiY., PanayiG.S., PitzalisC., KimuraT. (2002) The role of TNF-α in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology, 41, 329–337.
16.
VasanthiP., NaliniG., RajasekharG. (2007) Role of tumor necrosis factor-alpha in rheumatoid arthritis: a review. APLAR Journal of Rheumatology, 10, 270–274.
17.
CaporaliR., PallaviciniF.B., FilippiniM., GorlaR., MarchesoniA., FavalliE.G., Sarzi-PuttiniP., AtzeniF., MontecuccoC. (2009) Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal. Autoimmunity Reviews, 8, 274–280.
18.
HenniganS., KavanaughA. (2008) Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Therapeutics and Clinical Risk Management, 4, 767–775.
19.
NairA.B., JacobS. (2016) A simple practice guide for dose conversion between animals and human. Journal of Basic and Clinical Pharmacy, 7, 27–31.
